Activités de recherche

 Principales études 2015 - 2016 :

Etudes institutionnelles : 

Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials (COHVAC, NCT00789789) ANRS »

* Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults (SPLENEVAC, NCT02052154) APHP »

* Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults (AMA1-DiCo, NCT02014727) »

Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers (HYPOPNEUMO, NCT02279589) APHP »

Clinical Trial to Assess the Influenza Vaccination for Seasonal 2013-2016 (FLUVAC EV-03, NCT02027233) INSERM »

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (CONVERCE, NCT02537600) Center Eugene Marquis »

* Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults (PRIMALVAC, NCT02658253) INSERM »

GeneTB « Etude de l’influence de la génétique sur la prédisposition à la tuberculose » Institut Pasteur
Changing the coUrse of cRohn’s disease with an Early use of adalimumab:
The CURE study  Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives (G.E.T.A.I.D.)

ETUDE ANRS RF003 « IFN-VIH » Etude des sous types d’interférons de type I et de type
III produits par les cellules de sang périphérique de patients infectés par le VIH ANRS


Essais industriels :

- A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011, NCT 01254630) Merck »

- Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006, NCT01866319) Merck »

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD) (NCT01682083) GSK »

- Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (NCT02054286)Theravectys S.A. »

- Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection (NCT01887912) Sanofi Pasteur »

Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1 (NCT02390466) InnaVirVax » 

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma (NCT02416232) GSK »

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) (NCT02362594) Merck »

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation (STRIVE) (NCT02388165) Pfizer »

A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults (NCT02416453) Crucell Holland BV »

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection (NCT02532283) anssen Research & Development, LLC » 

Perspectives pour les 5 prochaines années :

  • Dans le cadre du partenariat avec l'Institut Pasteur, plusieurs essais vaccinaux sont prévus.

  • Le CIC est partenaire de 3 projets internationaux, financés par les Framework Programs de la Communauté Européenne.

  • Poursuite des recherches cliniques portant sur l'évaluation des vaccins, dans des populations fragiles. 

  • Développement de projets de recherche translationelle avec des équipes de recherche de l'Inserm, de l'Institut Pasteur et de l'Université Paris Descartes.pour mieux caractériser les réponses vaccinales. 

Page lue en 0,0756 seconde (4/0)